1 / 7

Transarterial Radioembolization (TARE) for Liver Transplant Candidates

Transarterial Radioembolization (TARE) is an advanced treatment option for patients with liver cancer, especially those awaiting liver transplants. TARE involves the delivery of radioactive microspheres directly into the liver tumor via the hepatic artery, providing localized radiation to shrink tumors and improve eligibility for liver transplantation. This procedure helps control tumor growth, enhances patient outcomes, and can bridge patients to transplantation, reducing the risk of disease progression. More information available at https://nuclearmedicinetherapy.in/

Nuclearmedicinetherapy
Download Presentation

Transarterial Radioembolization (TARE) for Liver Transplant Candidates

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nuclear Medicine Centre FMRi Gurugram INDIA Dr. Ishita B Sen Transarterial Radioembolization (TARE) for Liver Transplant Candidates www.nuclearmedicinetherapy.in

  2. Understanding TARE • TARE is a minimally invasive procedure that delivers targeted radiation therapy using Yttrium-90 (Y-90) microspheres directly to liver tumors via the hepatic artery. • Purpose: Aims to reduce tumor size and prevent progression, making patients eligible for liver transplantation. • Advantage: Preserves surrounding healthy liver tissue while effectively targeting cancer cells.​

  3. Role in Downstaging and Bridging • Downstaging: TARE can shrink tumors to meet transplantation criteria (e.g., Milan or UCSF), with success rates between 30%–50%. • Bridging: Helps maintain transplant eligibility during the waiting period by controlling tumor growth. • Comparison: Studies indicate lower dropout rates from transplant waitlists for TARE-treated patients compared to those receiving TACE.

  4. Post-Transplant Outcomes • Survival Rates: Patients undergoing TARE before transplantation have a 5-year survival rate exceeding 70%, comparable to non-cancerous transplant recipients. • Recurrence Rates: TARE-treated patients exhibit reduced tumor recurrence rates (15%–20%) post-transplant compared to TACE-treated patients (25%–30%). • Overall Benefit: Enhances long-term outcomes and quality of life post-transplantation.​

  5. Advantages Over Other Therapies • Lower Side Effects: TARE is better tolerated with fewer complications like post-embolization syndrome, which is common with TACE. • Preservation of Liver Function: Minimally impacts healthy liver tissue, maintaining liver function. • Cost-Effectiveness: Offers a more cost-effective solution with improved patient outcomes compared to traditional therapies.

  6. Conclusion • Summary: TARE is a vital tool in managing HCC patients awaiting liver transplantation, offering effective tumor control, improved survival rates, and better post-transplant outcomes. • Future Outlook: Continued research and clinical adoption of TARE can further enhance treatment protocols for liver transplant candidates.

  7. For more information talk to Dr. Ishita B Sen today. dr.ishitasen@nuclearmedicinetherapy.in +91 8700 668 431 www.nuclearmedicinetherapy.in

More Related